Welcome to our dedicated page for Iterum Therapeutics Plc SEC filings (Ticker: ITRMF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Iterum Therapeutics Plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Iterum Therapeutics Plc's regulatory disclosures and financial reporting.
Iterum Therapeutics plc notified Nasdaq of the removal of its Ordinary Shares from listing and/or registration on the Nasdaq Stock Market LLC pursuant to Form 25 and the cited rules 17 CFR 240.12d2-2. The Exchange certified compliance with its procedures for withdrawal.